Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver

This study has been terminated.

Study NCT00274495 Information provided by Beth Israel Medical Center

First Received: January 9, 2006 Last Updated: October 31, 2007 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been terminated.
Study Completion Date:	October 2007
Estimated Primary Completion Date:	No date given